Deals channel feed

Ab­b­Vie taps Jen­nifer Doud­na start­up for li­cens­ing deal worth up to $300M for 2 'off-the-shelf' CRISPR-edit­ed CAR-Ts

5 years ago
Cell/Gene Tx

Se­qens ma­jor­i­ty own­er look­ing to sell API mak­er amid record-high run in health­care val­u­a­tions: re­port

5 years ago
Manufacturing

Weighed down by safe­ty con­cerns of JAK port­fo­lio, Pfiz­er hatch­es a deal to go a dif­fer­ent di­rec­tion in rheuma­toid arthri­tis

5 years ago

Jazz vaults in­to the cannabi­noid field with $7.2B GW Phar­ma buy­out

5 years ago

Af­ter rais­ing $465M, Kurt von Em­ster talks about mon­ey, bio­phar­ma and a new breed of in­vestor: 'The ris­ing tide is push­ing every­body in­to this sec­tor'

5 years ago

Glax­o­SmithK­line dou­bles down on Cure­Vac's mR­NA tech, bets $180M on the hunt for next-gen vac­cine

5 years ago
Coronavirus
Manufacturing

WuXi STA snaps up Bris­tol My­ers Squibb fa­cil­i­ty, plants feet in Eu­ro­pean CD­MO mar­ket­place

5 years ago
Manufacturing

Ver­tex is poised for a shop­ping spree. But it’s still un­clear just what might go in­to their bas­ket — and at least one an­a­lyst is get­ting im­pa­tient

5 years ago

The packed PD-(L)1 game just got an­oth­er play­er — a low-pro­file biosim­i­lars com­pa­ny look­ing to branch out with a $150M cash pact

5 years ago

Hori­zon nabs an­oth­er rare dis­ease pipeline for the port­fo­lio in $3B buy­out. And As­traZeneca — a fu­ture ri­val — is get­ting about $780M of that

5 years ago

Biotech part­ner drops Glax­o­SmithK­line’s ad­ju­vant as it moves Covid-19 vac­cine in­to PhII/III, cit­ing ‘man­u­fac­tur­ing con­sid­er­a­tions’

5 years ago
Coronavirus

In pur­suit of an HIV cure, Gilead jumps in­to a T cell-dri­ving vac­cine pro­gram with a $785M deal that trig­gers PhI

5 years ago

Lil­ly at­tempts to re­vive an old idea for tack­ling pain, li­cens­ing PhI pro­gram from Japan’s Asahi Ka­sei Phar­ma

5 years ago

Top gene ther­a­py deals, M&A pacts in 2020 high­light an­oth­er big year in one of the hottest fields in bio­phar­ma

5 years ago
R&D

Dean Li kicks off Mer­ck­'s post-Roger Perl­mut­ter era by team­ing with Arti­va and its off-the-shelf CAR-NK tech

5 years ago

Psy­che­del­ic biotech ATAI hopes to ex­pand port­fo­lio through re­search part­ner­ship with Mass Gen­er­al

5 years ago

Fore­site re­turns to the SPAC well, as in­vestors won­der how long the run can last

5 years ago

Once laser-fo­cused on liv­er, Mi­NA takes swing at neu­rol­o­gy with Servier's back­ing

5 years ago

Grit­stone con­tin­ues Covid-19 push with deal to de­vel­op 'self-am­pli­fy­ing RNA' vac­cines, as shares con­tin­ue bal­loon­ing

5 years ago
Coronavirus

Lon­za hits the ex­it on gel and liq­uid cap­sules, of­fload­ing 2 pro­duc­tion sites to NextPhar­ma

5 years ago
Manufacturing

Eli Lil­ly tees up dis­cov­ery pact worth more than $1.6B with Merus for T cell-fo­cused bis­pe­cif­ic an­ti­bod­ies

5 years ago
Discovery

Pe­ter Thiel's psy­che­delics-fo­cused ATAI ac­quires ma­jor­i­ty stake in Recog­ni­fy and its lead schiz­o­phre­nia can­di­date

5 years ago

Look­ing to build in red-hot vi­ral vec­tor space, Ther­mo Fish­er inks $878M deal for Bel­gian man­u­fac­tur­er's 2 plants

5 years ago
Manufacturing

Acor­da of­floads man­u­fac­tur­ing op­er­a­tions to Catal­ent for $70M amid lat­est re­struc­tur­ing to keep the ship afloat

5 years ago
Manufacturing
First page Previous page 79808182838485 Next page Last page
A service from the Financial Times